Despite these strong fundamentals, Palantir’s stock is trading at an extremely lofty valuation compared with Morningstar’s fair value estimate. Khan pegs the stock’s fair value at $21, making for an ...
CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell therapies for the treatment of advanced solid tumors, today announced the appointment of Elena ...
Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...
Palantir shares moved lower in premarket trading Wednesday after falling sharply yesterday, as the stock continues to retreat from its record high set in late December. Monitor these key chart levels.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback